Suppr超能文献

胸腔镜手术下胸膜腔内高温化疗灌注治疗恶性胸腔积液的疗效。

Therapeutical effect of intrapleural perfusion with hyperthermic chemotherapy on malignant pleural effusion under video-assisted thoracoscopic surgery.

机构信息

a Hangzhou First People's Hospital, Nanjing Medical University , Hangzhou , PR China.

b Hangzhou Cancer Hospital , Hangzhou , PR China.

出版信息

Int J Hyperthermia. 2018 Jun;34(4):479-485. doi: 10.1080/02656736.2017.1340676. Epub 2017 Jul 5.

Abstract

BACKGROUND

Patients with malignant pleural effusions (MPEs) have limited life expectancy. This study aims to investigate the feasibility of intrapleural perfusion with hyperthermic chemotherapy (IPHC) under video-assisted thoracoscopic surgery on MPE patients.

METHODS

MPE patients were enrolled in the study and treated with IPHC. The treatment response was classified as complete response (CR, no re-accumulation of pleural fluid for 4 weeks), partial response (PR, re-accumulation above the post-IPHC level but below the pre-IPHC level for four weeks), no response (NR; re-accumulation or above the pre-IPHC level). The change of Karnofsky performance score (KPS) and tumour markers were also recorded. Follow-up was done every two weeks during first month and monthly thereafter until death.

RESULTS

Eighty patients included 46 males and 34 females were included in the study. The total response rate was 100%, with 71.3% of CR and 28.7% of PR. The KPS scores were significantly elevated and the level of tumour markers in pleural effusion were dramatically decreased after IPHC. The median survival was 16.8 months ranged from 2.1 to 67.4 months. One-year and two-year survival rates were 82.5% and 23.8%, respectively. There were no serious clinical compilations during IPHC treatment.

CONCLUSIONS

IPHC is a safety, effective and promising approach for MPE patients. It provides well survival benefit and minor toxicities.

摘要

背景

恶性胸腔积液(MPE)患者的预期寿命有限。本研究旨在探讨胸腔镜辅助下胸腔内热化疗(IPHC)治疗 MPE 患者的可行性。

方法

MPE 患者入组并接受 IPHC 治疗。治疗反应分为完全缓解(CR,4 周内无胸腔积液再积聚)、部分缓解(PR,4 周内胸腔积液再积聚高于 IPHC 后水平但低于 IPHC 前水平)和无反应(NR,胸腔积液再积聚或高于 IPHC 前水平)。还记录了卡氏功能状态评分(KPS)和肿瘤标志物的变化。在第一个月内每两周进行一次随访,此后每月进行一次,直到死亡。

结果

80 例患者包括 46 例男性和 34 例女性,总有效率为 100%,CR 为 71.3%,PR 为 28.7%。IPHC 后 KPS 评分显著升高,胸腔积液中肿瘤标志物水平显著降低。中位生存时间为 16.8 个月,范围为 2.1 至 67.4 个月。1 年和 2 年生存率分别为 82.5%和 23.8%。IPHC 治疗过程中无严重临床并发症。

结论

IPHC 是一种安全、有效、有前途的治疗 MPE 患者的方法。它提供了良好的生存获益和较小的毒性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验